Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HRMY vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HRMY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

HRMY Overall Winner 6-Pillar Tally: HRMY 6 – 0 AQST Matrix Metrics: HRMY 10 – 0 AQST

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).

  • Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HRMY vs AQST
HRMY NASDAQ Head-to-Head Winner
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
TTM Revenue $989M
Forward P/E 5.4x
Beta / 30D Vol 0.55β · 38% Vol
Unified Composite Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.1%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $34.97 · SMA50: $37.77
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23

6-Pillar Scorecard Institutional Category Breakdown (HRMY 6 – 0 AQST)

Columns: Metric · HRMY · AQST
1. Valuation Multiples HRMY
Forward P/E 5.4x N/M
Trailing P/E 10.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.5x 8.9x
2. Growth & Scale HRMY
Revenue Growth (YoY) +12.3% -41.0%
Earnings Growth (YoY) -6.9% +0.0%
TTM Revenue (USD) $989M $49M
Market Cap $1.9B $465.7M
3. Profitability & Quality HRMY
Gross Margin 74.0% 65.3%
Operating Margin 22.2% -114.1%
Net Profit Margin 18.1% -162.3%
Return on Equity (ROE) 18.7% 0.0%
4. Balance Sheet & Cash Flow HRMY
Cash Generation (TTM) $323M -$41M
Cash Flow Margin 32.6% -83.3%
Net Cash / Leverage $498M Net Cash $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HRMY
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 72.4% (11th %ile) 87.9% (64th %ile)
Put/Call OI Skew 4.40x (Put-Skewed) 0.98x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat HRMY
OpEx & R&D Intensity 51.8% of Rev ($512M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HRMY (10) vs AQST (0)
Institutional Metric HRMY AQST Criterion Row Edge
Market Capitalization
Scale
$1.9B $465.7M Larger Scale HRMY
Trailing P/E Ratio
Valuation
10.9x N/M Lower Multiple HRMY
Forward P/E Ratio
Valuation
5.4x N/M Lower Multiple HRMY
Revenue Growth (YoY)
Growth
+12.3% -41.0% Higher Growth HRMY
Operating Margin (TTM)
Profitability
22.2% -114.1% Higher Margin HRMY
Net Profit Margin
Profitability
18.1% -162.3% Higher Margin HRMY
Return on Equity (ROE)
Capital Efficiency
18.7% 0.0% Higher ROE HRMY
52-Week Range Position
Momentum
38% ($26–$43) 14% ($3–$7) Stronger Trend HRMY
Beta / 30D Volatility
Risk Regime
0.55β · 38% Vol 0.89β · 56% Vol Lower Realized Risk HRMY
Unified Institutional Score
Composite Signal
67.1 / 100 (BUY) 62.9 / 100 (BUY) Higher Composite HRMY
Trailing 12M Revenue (USD)
Operating Scale
$989M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.0% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev N/M PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$323M ($498M Net Cash) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HRMY +6.67 pp
HRMY: -9.55% · AQST: -16.22%
3M Horizon HRMY +12.57 pp
HRMY: -15.35% · AQST: -27.92%
6M Horizon HRMY +24.11 pp
HRMY: +8.09% · AQST: -16.02%
1Y Horizon HRMY +38.49 pp
HRMY: -2.16% · AQST: -40.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HRMY Revenue AQST Revenue HRMY Op. Margin AQST Op. Margin Margin Leader
FY2018 N/A $70M N/A -72.6% AQST
FY2019 $10M $50M -2433.8% -100.1% AQST
FY2020 $160M $50M 10.6% -93.6% HRMY
FY2021 $310M $50M 28.7% -68.2% HRMY
FY2022 $440M $50M 27.4% -88.2% HRMY
FY2023 $580M $50M 33.0% -29.9% HRMY
FY2024 $710M $60M 26.7% -53.5% HRMY
FY2025 $870M $40M 24.0% -159.5% HRMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HRMY CONSOLIDATION
114d in phase · OBV DISTRIBUTION
Current IV 72.4%
IV Percentile 11th %ile
Put/Call OI Skew 4.40x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HRMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $33.20 · IV 76.7%

HRMY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,320)

Compare $3,320 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 76.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 30d

Net Entry $60 Credit
Max Credit / Yield +$60 (+13.6% RoM)
Max Risk / Buffer -10.5% Cushion ($440 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $35 / $30 Bear Put Spread

Buy 1x $35P · Sell 1x $30P · 30d

Net Entry $230 Debit
T+5d @ -5% Drop +$67 (+29%)
Max Risk / Buffer $230 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HRMY Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 22.2% operating margin.
OpEx & R&D Reinvestment 51.8% of Rev ($512M)
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HRMY vs AQST Key Questions & Quantitative Answers

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HRMY leads the Growth & Scale pillar: HRMY posts +12.3% YoY revenue growth and -6.9% YoY earnings growth on $989M TTM revenue (74.0% gross margin, 22.2% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), HRMY cumulative revenue shifted +8600.0% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, HRMY deploys 51.8% of Rev ($512M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

HRMY screens cheaper on headline valuation multiples. HRMY trades at 5.4x Forward P/E, 10.9x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (32.6% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HRMY (18.7% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, HRMY carries 72.4% implied volatility (11th %ile, Compressed (<25th %ile)), a 4.40x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.55β · 38% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.